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Abstract Ebstein’s anomaly is a rare congenital heart
malformation characterised by adherence of the septal and
posterior leaflets of the tricuspid valve to the underlying
myocardium. Associated abnormalities of left ventricular
morphology and function including left ventricular non-
compaction (LVNC) have been observed. An association
between Ebstein’s anomaly with LVNC and mutations in
the sarcomeric protein gene MYH7, encoding β-myosin
heavy chain, has been shown by recent studies. This might
represent a specific subtype of Ebstein’s anomaly with a
Mendelian inheritance pattern. In this review we discuss the
association of MYH7 mutations with Ebstein’s anomaly and
LVNC and its implications for the clinical care for patients
and their family members.
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Introduction
Ebstein’s anomaly is a rare congenital heart malformation
affecting about 1 in 200,000 live births [1]. Associated
abnormalities of left ventricular morphology and function
including left ventricular noncompaction (LVNC) have
been reported [2–6]. Recently, mutations in the sarcomeric
protein gene β-myosin heavy chain (MYH7) were described
in patients with Ebstein’s anomaly associated with LVNC
[5, 7]. Here, we will discuss this association and focus on
its implications for the clinical care of patients with
Ebstein’s anomaly and their family members.
Ebstein’s anomaly and LVNC
Ebstein’s anomaly is characterised by apical displacement
and adherence of the septal and posterior leaflets of the
Fig. 1 Images of a 24-year-old woman with an MYH7 mutation from
the study of Postma et al. [7] This patient was a relative of one of the
probands with Ebstein’s anomaly, LVNC and MYH7 mutation. She
was asymptomatic and identified as a mutation carrier by family
screening. a) MRI image, 4-chamber view; Ebstein anomaly is present
(shown by apical displacement of the septal leaflet of the tricuspid
valve from the insertion of the anterior leaflet of the mitral valve), as
well as LVNC. b) Echocardiographic images, apical 4-chamber view;
Ebstein’s anomaly and LVNC are evident. There is also noncompac-
tion of the right ventricle. c) Colour Doppler image, showing
trabecularisation and recesses filled with blood in the left ventricle.
Large arrow, mitral valve; small arrow, tricuspid valve; triangles,
LVNC; LV, left ventricle; LV, left atrium, RA, right atrium T
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tricuspid valve to the underlying myocardium, thereby
displacing the functional tricuspid orifice apically and
dividing the right ventricle into two portions [1]. The main
haemodynamic abnormality leading to symptoms is tricus-
pid valve incompetence. The clinical spectrum is broad;
patients may be asymptomatic or experience right-sided
heart failure, cyanosis, arrhythmias and sudden cardiac
death (SCD) [1]. Many Ebstein’s anomaly patients have an
interatrial communication (secundum atrial septal defect
(ASD II) or patent foramen ovale). Other structural
anomalies may also be present, including bicuspid aortic
valve (BAV), ventricular septal defect (VSD), and pulmo-
nary stenosis [1, 8]. The genetic aetiology of Ebstein’s
anomaly is largely unknown. Most cases are sporadic and
familial Ebstein’s anomaly is rare. Genetic, environmental
and reproductive factors are all believed to be contributing
[9]. Patients with non-syndromic Ebstein’s anomaly are
generally thought to have a small risk (a few percent) of
transmitting heart disease to their offspring [10]. Rare
mutations in the transcription factor gene NKX2.5 have
been described in a variety of patients with congenital heart
disease (CHD) including Ebstein’s anomaly [11], while
chromosomal abnormalities have also been reported [12,
13]. Among the nongenetic causes of Ebstein’s anomaly are
intrauterine infections or exposure to lithium [14].
An association between Ebstein’s anomaly and left
ventricular noncompaction (LVNC) has been reported in
several studies [2–6]. LVNC is classified as a primary
cardiomyopathy with a genetic aetiology [15], featuring a
thickened two-layered myocardium with a thin, compact,
epicardial layer and a severely thickened endocardial layer
with a ‘spongy’ appearance due to prominent trabeculations
and intertrabecular recesses [16]. Clinical features are
variable and include heart failure, arrhythmias and throm-
boembolism, but patients can also be asymptomatic [17,
18]. Up to 64% of isolated LVNC has been reported to be
familial, mostly consistent with an autosomal dominant
mode of inheritance [18]. Mutations in several genes
coding for sarcomeric proteins have been described in
LVNC, such as β-myosin heavy chain (MYH7), cardiac
myosin-binding protein C (MYBPC3), α-cardiac actin
(ACTC1), cardiac troponin T (TNNT2), α-tropomyosin
(TPM1) and cardiac troponin I (TNNI3) [18–21]. MYH7
has been reported to be the most frequent disease gene in
LVNC in the absence of CHD [18, 19].
MYH7 mutations in Ebstein’s anomaly associated
with LVNC
Although an association between Ebstein’s anomaly and
LVNC has been suggested by previous studies, a common
genetic origin was not elucidated until recently. In 2007
Budde et al. [5] investigated a large three-generation family
with 12 affected patients with LVNC. Four family members
had Ebstein’s anomaly with or without ASD in addition to
LVNC, and one patient had an ASD with LVNC. In total,
24 family members were assessed and genome-wide
analysis showed linkage to chromosome 14ptel-14q12.
One of the genes sequenced in this locus was MYH7, and
a previously unknown heterozygous missense mutation was
found, segregating with the condition within the family.
The authors thereby detected a new phenotype that had not
been known to be related to MYH7 before. These findings
by Budde et al. [5] led our group to further investigate the
association between Ebstein’s anomaly and MYH7 muta-
tions. We performed mutational analysis using next
generation sequencing and direct DNA sequencing of
MYH7 in a cohort of 141 unrelated Ebstein’s anomaly
patients [7]. We identified heterozygous mutations in 8 of
141 patients (6%). In 6 of 8 probands LVNC was identified
in addition to Ebstein’s anomaly, one proband had partially
penetrant LVNC and in another proband LVNC was
uncertain. The probands’ families were studied, and
familial CHD and/or LVNC was present in 3 of 5 families
that were available for study. In these kindreds MYH7
mutations segregated with LVNC and CHD (Fig. 1).
Familial Ebstein’s anomaly was present in one family,
while several other types of CHD were encountered in the
probands and their relatives, including ASD II, perimem-
branous VSD, pulmonary artery hypoplasia and coarctation
of the aorta with BAV (Table 1). Most of the family
Table 2 Sporadic cases with MYH7 mutation and Ebstein’s anomaly
Individual Mutation Phenotype Reference
AO 1220delGlu Ebstein’s anomaly, LVNC Postma et al. [7]
DB Tyr350Asp a Ebstein’s anomaly, LVNC Postma et al. [7]
BT Leu390Pro Ebstein’s anomaly, LVNC, PFO Postma et al. [7]
AD Lys1459Asn Ebstein’s anomaly, left ventricular morphology undetermined Postma et al. [7]
LVNC left ventricular noncompaction; PFO patent foramen ovale
a De novo mutation
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members shown to have LVNC, as well as the relative with
Ebstein’s anomaly, were not known to have cardiac disease
before family screening. No MYH7 mutations were found
in the remaining 133 Ebstein’s probands, in whom LVNC
had not been reported. Recently, Hoedemaekers et al. also
reported a family with an MYH7 mutation segregating with
LVNC and one individual also having Ebstein’s anomaly
[18]. An overview of the reported families and sporadic
patients with MYH7 mutations and Ebstein’s anomaly is
given in Tables 1 and 2, respectively.
The results of these studies suggest that there is a
specific subtype of Ebstein’s anomaly, with LVNC and an
autosomal dominant inheritance pattern, caused by muta-
tions in MYH7. The Ebstein’s anomaly phenotype is not
fully penetrant though, as only a minority of mutations
carriers have Ebstein’s anomaly. Additionally, other CHD
may be part of the condition as well. This variable
expression suggests that other genetic or environmental
factors probably play a role in the establishment of the final
phenotype. How mutations in MYH7 can produce Ebstein’s
anomaly should be subject of further study. LVNC is
thought to result from altered regulation in cell prolifera-
tion, differentiation and maturation during ventricular wall
formation [22], and an arrest in directional growth may play
a role in the association of Ebstein’s anomaly and LVNC
[23, 24].
With the identification of MYH7 mutations in Ebstein’s
anomaly with LVNC, the spectrum of phenotypes with a
defect in a structural protein has been broadened. While
sarcomeric mutations are well-known causes of cardiomy-
opathies, it was not until recently that several of these genes
were found to play a role in various forms of CHD.
Mutations in MYBPC3, ACTC1 and α-myosin heavy
chain (MYH6) have been implicated in septal defects
[25–27], while mutations in ACTA2 and MYH11, genes
encoding sarcomeric proteins of smooth muscle cells, can
lead to aortic aneurysm with patent ductus arteriosus
[28, 29]. How these sarcomeric mutations contribute to the
development of CHD is unclear and should be subject to
further research.
Clinical implications
LVNC is a familial disease with potentially severe
complications, including severe arrhythmias, heart failure
and thromboembolism [17, 18, 30]. These complications
may be prevented by early diagnosis and timely treatment
of high-risk patients, such as anticoagulants in patients at
risk for thromboembolism [17] and implantation of an
implantable cardioverter defibrillator in those at risk for
life-threatening arrhythmias [30]. ACE inhibitors, β-
blockers and diuretics can be of use in patients with left
ventricular dysfunction [17]. We therefore recommend
detailed clinical evaluation of all Ebstein’s anomaly patients
to identify possible additional LVNC. If LVNC is identi-
fied, genetic counselling of the patient as well as his or her
relatives should be carried out [18, 31]. Genetic counselling
should be performed by trained professionals in a multi-
disciplinary environment, ideally in a centre specialised in
cardiogenetics [31]. In patients with Ebstein’s anomaly and
LVNC, we recommend initiating genetic testing with
MYH7, and other genes implicated in LVNC to be screened
if no mutation in MYH7 is found. If a disease-causing
mutation is established, apparently healthy relatives at risk
for the disease can subsequently be identified reliably.
Relatives who carry the mutation should have regular
medical follow-up to detect cardiac abnormalities at an
early stage. In the absence of an identified genetic cause of
LVNC, or when relatives decline genetic testing, regular
medical follow-up is also warranted. Predictive genetic
testing of asymptomatic family members should only be
performed after counselling about potential benefits (e.g.
medical benefits of early diagnosis) as well as about
possible adverse implications (insurance, employment,
psychological consequences) [18, 31].
Conclusions
Recent studies have identified MYH7 mutations as a
cause of Ebstein’s anomaly associated with LVNC and
other CHD. This condition might represent a specific
subtype of Ebstein’s anomaly. The inheritance pattern is
autosomal dominant, though with a variable penetrance
and phenotype, some family members showing only
partially penetrant LVNC and others having LVNC with
additional CHD. We recommend patients with Ebstein’s
anomaly to be carefully evaluated for LVNC, and if
present, early treatment of patients at risk for complica-
tions of LVNC. Moreover, genetic counselling and
genetic testing should be performed by trained profes-
sionals, preferably in a multidisciplinary setting in a
centre specialised in cardiogenetics. Subsequently, genetic
counselling and cardiological evaluation of relatives or, if
a mutation is found in the proband, genetic testing of
relatives is warranted. Further studies are needed to
investigate if mutations in other (sarcomere) genes than
MYH7 can also lead to Ebstein’s anomaly with or
without LVNC.
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